Results 51 to 60 of about 2,428,275 (198)

Unravelling the mechanisms of resistance to imatinib mesylate in chronic myeloid leukemia: a proteomic approach [PDF]

, 2010
Imatinib mesylate is a potent inhibitor of the Bcr-Abl tyrosine kinase, an oncoprotein that plays a key role in the development of chronic myeloid leukemia. Consequently, imatinib is used as front-line therapy for this disease.
Colavita, Irene
core   +1 more source

Co-existence of AML1-ETO and BCR-ABL1 transcripts in a relapsed patient of acute myeloid leukemia with favorable risk group: A coincidence or clonal evolution?

Hematology/Oncology and Stem Cell Therapy, 2017
Prognosis of acute myeloid leukemia relies heavily on the cytogenetic and molecular abnormalities. AML1-ETO fusion protein resulting from t(8;21), a recurring cytogenetic abnormality, is known to be associated with favorable prognosis.
Manish K. Singh, Ruchi Gupta, Khaliqur Rahman, Sanjeev Kumar, Akhilesh Sharma, Soniya Nityanand   +5 more
doaj   +1 more source

BCR ABL Fusion Protein Detection by a Modern Approach: Fluroscent Immuno Bead Assay

Annals of Oncology, 2012
ABSTRACT Introduction Chronic Myeloid Leukemia (CML) is probably the most extensively studied human malignancy. CML patients (90-95%) harbor the Philadelphia (Ph) chromosome, a shortened chromosome 22, resulting from a reciprocal translocation t (9; 22) (q34; q11) between the long arms of chromosome 9 and 22, fusion ABL proto-oncogene on chromosome ...
S. Dasgupta, U.K. Ray, A. Mukhopadhyay, J. Basak, S. Mukhopadhyay   +4 more
openaire   +1 more source

Multi‐omics–driven precision medicine

iMeta, EarlyView.
Multi‐omics‐driven precision medicine (MODPM) provides a multiscale, continuously learnable framework that integrates genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome profiles, and clinical data. Powered by artificial intelligence and foundation models, MODPM enables cross‐modal representation learning, contextual modeling ...
Huibo Li, Zhe Zhao, Yifan Zhang, Yao Ma, Gaofei Hu, Min Zeng, Zhanqun Yang, Zixuan Zhao, Xin Zhou, Wei Hu, Yuxuan Sun, Meng Su, Jun Li, Matthew Whiteman, Wei Fu, Chao Zhong, Lemin Zheng, Long Chen, Hairong Lv, Rongsheng Zhao, Yi Zhun Zhu   +20 more
wiley   +1 more source

Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia [PDF]

, 2013
Purpose: Aberrant PI3K/AKT/mTOR signaling has been linked to oncogenesis and therapy resistance in various malignancies including leukemias. In Philadelphia chromosome (Ph) positive leukemias, activation of PI3K by dysregulated BCR-ABL tyrosine kinase ...
Oliver G Ottmann, Martin Ruthardt, Oliver G. Ottmann, Oliver G. Ottmann (485229), Falkenburg, J.H.F., Marcus Liebermann (485228), Bart A. Nijmeijer (485227), Pfeifer, Heike, Falkenburg, J. H. Frederik, J. H. Frederik Falkenburg, Ruthardt, Martin, Tamara Tesanovic, Tesanovic, Tamara, Bart A Nijmeijer, Heike Pfeifer, Ottmann, Oliver G., Susanne Badura (485223), Sylvia Wystub, Sylvia Wystub (485226), Liebermann, M., Marcus Liebermann, Bart A. Nijmeijer, Ottmann, O.G., Nijmeijer, Bart A., Badura, S., Susanne Badura, Wystub, Sylvia, Pfeifer, H., J H Frederik Falkenburg, Tamara Tesanovic (485224), Martin Ruthardt (66634), Wystub, S., Nijmeijer, B.A., Ruthardt, M., Tesanovic, T., Badura, Susanne, Heike Pfeifer (485225), J. H. Frederik Falkenburg (210432), Liebermann, Marcus   +38 more
core   +1 more source

Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques.

PLoS ONE, 2015
Chronic Myeloid Leukemia (CML) is characterized by a balanced translocation juxtaposing the Abelson (ABL) and breakpoint cluster region (BCR) genes.
Anna Grazia Recchia, Nadia Caruso, Sabrina Bossio, Mariavaleria Pellicanò, Laura De Stefano, Stefania Franzese, Angela Palummo, Vincenzo Abbadessa, Eugenio Lucia, Massimo Gentile, Ernesto Vigna, Clementina Caracciolo, Antolino Agostino, Sara Galimberti, Luciano Levato, Fabio Stagno, Stefano Molica, Bruno Martino, Paolo Vigneri, Francesco Di Raimondo, Fortunato Morabito   +20 more
doaj   +1 more source

Two different point mutations in ABL gene ATP-binding domain conferring Primary Imatinib resistance in a Chronic Myeloid Leukemia (CML) patient: A case report

Biological Procedures Online, 2004
Imatinib (Gleevec) is the effective therapy for BCR-ABL positive CML patients. Point mutations have been detected in ATP-binding domain of ABL gene which disturbs the binding of Gleevec to this target leading to resistance.
Iqbal Zafar, Siddiqui Rubina T., Qureshi Javed A.   +2 more
doaj   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, EarlyView.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Post‐Hoc Long‐Read Sequencing Links Leukemic Mutation Status to Single‐Cell Transcriptomes

European Journal of Haematology, EarlyView.
ABSTRACT Single‐cell RNA‐sequencing‐based characterization of cells that belong to the neoplastic clone is a major challenge in hematologic neoplasms, where malignant and normal cells coexist. Confident molecular profiling requires simultaneous analysis of gene expression and genetic mutations in individual cells, an ability that is not supported by ...
Sofia Papavasileiou, Chenyan Wu, Daryl Boey, Lucille Margerie, Jiezhen Mo, Ulla Olsson‐Strömberg, Stina Söderlund, Gunnar Nilsson, Joakim S. Dahlin   +8 more
wiley   +1 more source

Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital

Revista Brasileira de Hematologia e Hemoterapia, 2013
Objetive: The aim of this study was to identify the reasons for failure in adherence to imatinib mesylate treatment in chronic myeloid leukemia. Methods: A retrospective review was performed of
Samuel Roosevelt Campos dos Reis, Acy Telles de Souza Quixada, Sammara Tavares Nunes, Danielle Maria Camelo Cid, Jacqueline Holanda de Souza, Clara Maria Bastos Eloy da Costa, Carolina Bizelli Silveira, David Antonio Camelo Cid, Mariana Fatima Cabral de Oliveira   +8 more
doaj   +1 more source